# A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis

> **NCT01045577** · PHASE2 · COMPLETED · sponsor: **AB Science** · enrollment: 25 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Masitinib
- **DRUG:** Masitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01045577
- **Lead sponsor:** AB Science
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2006-01
- **Final completion:** 2008-02
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2018-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01045577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01045577, "A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01045577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*